Phaseline

Companies › Targeted Therapy Technologies

Targeted Therapy Technologies: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Nov 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Topotecan
DNA topoisomerase I inhibitor
TOP1Phase 2RetinoblastomaNov 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06679634TopotecanPhase 2RetinoblastomaOncologyNov 2029

Targets

TOP1 (1)

Companies with the same targets

Daiichi Sankyo AstraZeneca Merck & Co. (MSD) Gilead Sciences Klus Pharma Fujifilm Pharmaceuticals U.S.A. Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair CEBIOTEX Sichuan Kelun-Biotech Biopharmaceutical Luye Pharma Group

Companies built like this

CEBIOTEX CNS Pharmaceuticals NanoEcho Syncromune Galecto Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.